Oligodendrocytes are the myelinating cells of the CNS that enable formation of myelin and saltatory nerve conduction. In humans, premyelinating oligodendrocytes are most abundant at the gestational age of 23-32 weeks and are thought to be selectively vulnerable during injury in the neonatal brain 1 . Hypoxic ischemic encephalopathy (HIE) causes neuronal apoptosis as well as diffuse primary damage to subcortical white matter in the term infant brain, whereas periventricular leukomalacia (PVL) comprises focal injury to white matter tracts as well as diffuse gliotic lesions, typically in premature infants 2 . Such diffuse and focal injuries, collectively known as white matter injury (WMI) in the newborn brain, can result in cerebral palsy and cognitive disability. Indeed, WMI is the most reliable prognostic indicator of development of severe cerebral palsy in premature infants 3 . In multiple sclerosis, the most common cause of neurological disability in young adults, myelin sheaths are lost through the injury or death of mature oligodendrocytes that results from autoimmune damage 4 .
In these conditions, myelin sheaths can be regenerated by OLPs that are recruited to lesions and differentiate in a process called remyelination. Conversely, inhibition of remyelination may contribute to ongoing neurological dysfunction, axonal loss and disease progression 5, 6 . Although oligodendrocytes are thought to be cellular targets of excitotoxic damage in newborn brain injuries 2, 7 , several lines of evidence indicate that failure of remyelination contributes to fixed demyelinated lesions 8, 9 . Indeed, non-myelinating OLPs can be found in both PVL 8, 9 and multiple sclerosis 5, 6 lesions.
The molecular mechanisms that might dysregulate myelination in neonatal brain injury are unknown. Previously, we found that active Wnt signaling can act to inhibit OLP differentiation during remyelination in the adult rodent CNS 10 , and several studies have shown that Wnt activation inhibits developmental myelination [10] [11] [12] . In the absence of Wnt ligands, β-catenin levels are regulated through a phosphorylation/degradation complex 13, 14 containing glycogen synthase kinase 3β (GSK-3β) and the scaffolding proteins Axis inhibition protein 1 (Axin1), adenomatous polyposis coli (APC) and disheveled (Dsh) . The presence of Wnt ligand results in stabilization of β-catenin and its translocation to the nucleus, where it forms a nucleoprotein complex with Tcf/LEF transcription factors to activate or repress the expression of target genes 15, 16 . Axin1 is expressed ubiquitously, whereas Axin2 (also known as conductin) is a transcriptional target of active Wnt signaling that also serves to autoregulate and repress the pathway by promoting β-catenin degradation in many different tissues and systems 14, [17] [18] [19] . Dual roles for signaling targets that also serve as feedback repressors are seen in other pathways, such as Sonic hedgehog (Shh), which activates the repressors Patched and Gli3 (ref. 20) .
We observed expression of AXIN2 mRNA transcripts in situ in OLPs in WMI associated with human neonatal HIE and PVL, as well as in active multiple sclerosis lesions in adults. Although Axin2 function has been reported as being dispensable during brain development 21 , we found Axin2 function to be essential for normal myelination and remyelination in mice. Moreover, Axin2 levels can be manipulated Permanent damage to white matter tracts, comprising axons and myelinating oligodendrocytes, is an important component of brain injuries of the newborn that cause cerebral palsy and cognitive disabilities, as well as multiple sclerosis in adults. However, regulatory factors relevant in human developmental myelin disorders and in myelin regeneration are unclear. We found that AXIN2 was expressed in immature oligodendrocyte progenitor cells (OLPs) in white matter lesions of human newborns with neonatal hypoxic-ischemic and gliotic brain damage, as well as in active multiple sclerosis lesions in adults. Axin2 is a target of Wnt transcriptional activation that negatively feeds back on the pathway, promoting -catenin degradation. We found that Axin2 function was essential for normal kinetics of remyelination. The small molecule inhibitor XAV939, which targets the enzymatic activity of tankyrase, acted to stabilize Axin2 levels in OLPs from brain and spinal cord and accelerated their differentiation and myelination after hypoxic and demyelinating injury. Together, these findings indicate that Axin2 is an essential regulator of remyelination and that it might serve as a pharmacological checkpoint in this process. 1 0 1 0 VOLUME 14 | NUMBER 8 | AUGUST 2011 nature neurOSCIenCe a r t I C l e S pharmacologically in OLPs to promote accelerated differentiation, suggesting that Axin2 serves as a therapeutic target in situations in which OLP differentiation is delayed or stalled.
RESULTS
AXIN2 mRNA marks OLP in human neonatal WMI Previously, we found Wnt pathway activation using the transgenic BAT-gal reporter (β-catenin-activated transgene driving lacZ) in developing OLPs in vivo and that forced activation of the canonical Wnt pathway during development of transgenic Olig2-cre; DA-cat mice (see Online Methods) inhibits differentiation of OLPs to mature oligodendrocytes 10 . Expression profiling of postnatal day 4 (P4) spinal cord from these mice revealed significant (P < 0.00006) downregulation of multiple genes associated with oligodendrocyte maturation ( Supplementary Table 1 and Supplementary Fig. 1 ), including Mbp, Plp, Cnp, Mog, Mag, Mobp, Fa2h, Mal and the transcription factor Mrf 22 . This analysis also identified known Wnt-activated targets, such as Nkd1, Notum and Axin2, as being significantly upregulated (P < 0.0002). In contrast, changes in expression of the Wnt pathway antagonist gene adenomatous polyposis coli (Apc, also known as CC1) were not significant.
Using expression of AXIN2 mRNA transcripts to mark Wnt-activated white matter cells in situ, we investigated two types of human neonatal brain injury that are characterized by white matter damage and injury to oligodendrocyte lineage cells, resulting in hypomyelination ( Supplementary Fig. 2 ). AXIN2 mRNA was solely expressed in Olig2positive cells in affected white matter in neonatal HIE and PVL (note that staining in PVL localized adjacent to the cystic core of lesion; Fig. 1a-c) , but not white matter in age-matched controls (Fig. 1a,c) . In the HIE samples, AXIN2 mRNA was expressed in a subset of the Tcf4-positive cells ( Fig. 1d) , consistent with activation of canonical Wnt signaling. AXIN2 mRNA segregated from the mature oligodendrocyte marker PLP in situ ( Fig. 1e ) and segregated completely from GFAP ( Fig. 1f) . Similarly, the independent Wntactivated target Naked1 (Nkd1) was expressed in PDGFRα-positive OLPs, but not in astroglia ( Fig. 1g,h and Supplementary Fig. 3 ). The expression of these Wnt targets provides strong evidence that the Wnt pathway is activated specifically in immature, pre-myelinating OLPs in human neonatal WMI ( Supplementary Fig. 4) , and that they can be used to assess human neuropathological specimens ( Supplementary Fig. 5 ).
Axin2 function is required for OLP differentiation Axin2 mRNA serves as a marker for pathway activation, whereas Axin2 protein functions as a negative feedback mechanism to control activation of the Wnt pathway via β-catenin degradation 17, 18 . Using wildtype and Axin2-lacZ heterozygous mice 18 , we characterized Axin2 mRNA and reporter gene expression during developmental myelination ( Fig. 2a-d) . Axin2 mRNA was expressed in immature Nkx2.2positive OLPs, but not CC1-positive differentiated oligodendrocytes ( Fig. 2b) . In contrast, β-galactosidase was first detectable at the later CC1-positive stage (Fig. 2c,d and Supplementary Fig. 6 ).
Axin2-lacZ homozygous null mice showed a significant (P = 0.007) delay in OLP differentiation during developmental myelination ( Fig. 2e,f and Supplementary Fig. 7) . Moreover, as indicated by coexpression of β-galactosidase with PDGFRα ( Fig. 2g) , the reduction in mature oligodendrocyte numbers reflects a delay in OLP maturation rather than decreased OLP numbers. Indeed, there was no difference in apoptosis or proliferation of the OLP pool ( Supplementary Fig. 8 ).
We also observed a significant (P < 0.005) impairment of Axin2 −/− oligodendrocyte differentiation in vitro (Fig. 2h,i) , and strong activation of the independent Wnt target Notum (Fig. 2j) . Thus, Axin1 a r t I C l e S is unable to compensate for the loss of early Axin2 functions in oligodendrocyte differentiation in vitro or in vivo.
Axin2 expressed in multiple sclerosis and functions in myelin repair
Previous studies have found that lesions of both neonatal PVL and adult multiple sclerosis have OLPs that are evidently 'stalled' in their differentiation 5, 6, 8, 9 , which has been proposed to result in defective repair and fixed demyelinated lesions 23 . Thus, we focused on regulatory functions of Axin2 in the context of primary damage to oligodendrocytes. We confirmed that AXIN2 mRNA transcripts are expressed in OLP in active multiple sclerosis lesions ( Fig. 3a,b) , in which oligodendrocytes are targeted for autoimmune attack. Axin2 mRNA-expressing cells were not seen in areas of normal-appearing white matter or in chronic silent plaques ( Fig. 3a) . A similar pattern of expression was seen for the independent Wnt-activated target Naked1 (Nkd1). Naked1-expressing cells were seen at active multiple sclerosis lesion edges ( Fig. 3c and Supplementary Fig. 5) , with the simple bipolar morphology that is characteristic of OLP (Fig. 3c) , and at a similar cellular density as Axin2 mRNA-expressing cells ( Fig. 3c) .
Remyelination can be investigated after adult murine lysolecithin injury ( Fig. 4) , which kills resident oligodendrocytes while leaving axons largely intact. Such lesions in spinal cord ventral or dorsal white matter have been extensively characterized 24 and revealed OLP recruitment (5 days post lesion, dpl), differentiation (10 dpl) and myelination (14 dpl) with stereotyped timing in young adult animals ( Fig. 4a ), allowing precise assessment of remyelination kinetics. In adult animals, we observed robust expression of the β-galactosidase reporter in Axin2-lacZ heterozygote mice 10 d after Although mature oligodendrocyte numbers normalized by 8 weeks of age in Axin2 −/− animals ( Fig. 4f and Supplementary Fig. 9 ), Axin2 −/− mice showed significantly delayed remyelination (P < 0.05) compared with wild-type littermates ( Fig. 4c and Supplementary Fig. 10 ) as a result of a delay in Nkx2.2-positive OLP differentiation (with normal OLP recruitment) in lesions at 10 and 14 dpl ( Fig. 4c-f ). The inflammatory cell and astrocyte response in lesions was not affected in Axin2 −/− mice ( Supplementary Fig. 11 ), suggesting that the delay in remyelination in Axin2 −/− animals is attributable to a cell-autonomous requirement in OLPs.
Axin2 protein stabilization promotes OLP differentiation
We next investigated whether enhanced Axin2 activity might promote accelerated oligodendrocyte maturation. Axin2 and Axin1 were recently identified as substrates for the poly-ADP-ribosylating enzymes tankyrase 1 and 2 (ref. 25) , which promote Axin degradation through the ubiquitin-proteosome pathway. XAV939 inhibited tankyrase activity in cell lines at a concentration of 5 µM, resulting in stabilized Axin protein levels 25 . a r t I C l e S Tankyrase was expressed in the rodent oligodendrocyte lineage during development, commencing at a mature stage (Fig. 5a,b) , and continued to be expressed in oligodendrocytes in adult white matter (S.P.J.F. and D.H.R., unpublished observations). Tankyrase was also expressed in early differentiating oligodendrocytes following demyelination in the adult spinal cord white matter of the mouse (Fig. 5c) .
Given these findings, we tested the effects of XAV939 on stabilizing Axin protein levels in OLPs in vitro. Treatment with XAV939 (0.01 or 0.1 µM) for 24 h produced increases in the levels of both Axin2 and Axin1 proteins in OLPs versus vehicle controls, and increased protein levels of tankyrase 1 and 2, presumably as a result of a reduction in their autoparsylation and self-induced degradation (Fig. 5d) 25 . XAV939 treatment of OLPs resulted in increased levels of phospho-βcatenin and β-catenin degradation, as well as reductions in the levels of Axin2 mRNA transcripts (Fig. 5e ) and the activity of a transduced Topflash reporter (data not shown), indicating that the Wnt pathway was inhibited. Moreover, in addition to these early effects on Wnt pathway per se, XAV939 treatment promoted precocious oligodendrocyte differentiation (Fig. 5f-h) , as evidenced by increased expression of the mature oligodendrocyte marker myelin basic protein (MBP).
We next confirmed tankyrase protein expression in the human oligodendrocyte lineage during neonatal WMI. Tankyrase was expressed in later stage oligodendrocyte cells that expressed NOGO-A and cytoplasmic Olig1 (Fig. 5i) . Conversely, tankyrase expression was not observed in inflammatory macrophages, microglia or reactive astrocytes in gliotic areas of white matter damage. These data suggest that pharmacological manipulation of Axin2 levels in OLPs through tankyrase inhibition has therapeutic potential in human neonatal WMIs.
To address this question, we investigated the effects of XAV939 on OLPs in mouse cerebellar slice cultures (Fig. 6 ). In this system, slices of P0-1 neonatal cerebellum are cultured in the presence of factors that can affect remyelination of cerebellar white matter 26 . We examined the ratio of neurofilament 200 kDa (NFH)-positive axons that coexpressed myelin basic protein (MBP) and measured the density of the nodes of Ranvier, indicated by Caspr-positive paranodes. XAV939 treatment (0.01 µM) significantly increased myelination compared with controls (P < 0.001; Fig. 6a) . Moreover, we observed that acute hypoxic exposure (2% oxygen for 24 h) reduced myelination to levels significantly below controls (P < 0.01; Fig. 6a,b) . We suggest that the effect of hypoxia in this system is primarily a result of inhibition of Fig. 6b ). Treatment with XAV939 reversed the effect of hypoxia and increased the extent of myelinated axons to well above control levels. To determine whether XAV939 treatment can act on cerebellar OLPs to promote remyelination, we also tested its effects after addition of 0.5% lysolecithin to culture medium to induce toxic injury to oligodendrocytes (Fig. 6c) .
In this procedure, XAV939 also promoted a significant enhancement of myelin regeneration (P < 0.001; Fig. 6c ).
As illustrated above (Fig. 4a) , the kinetics of remyelination in vivo in focal toxic injury models is tightly regulated and, to the best of our knowledge, no drugs have been reported that accelerate OLP differentiation. To test whether pharmacologic stabilization of Axin might promote OLP differentiation during remyelination in vivo, we co-injected young adult (8-10 weeks old) mouse spinal cord lysolecithin lesions with XAV939 (0.1 µM; Fig. 7) . We observed a notable increase in PLP-positive differentiated oligodendrocytes as early as 6 dpl in XAV939-treated dorsal and ventral lesions compared with vehicle-treated controls (Fig. 7a,c) . Moreover, such XAV939 effects were Axin2 dependent, as Axin2 −/− mice showed markedly less OLP differentiation at 6 dpl following lysolecithin treatment versus controls (Fig. 7b,c) . This increase in mature oligodendrocyte numbers at 6 dpl was a result of a precocious differentiation of recruited OLP rather than an increased survival of existing oligodendrocytes (Fig. 7g) . Although total Olig2-positive cells were similar at 6 dpl in XAV939-treated lesions and controls, XAV939 produced a shift in the proportion of Olig2-positive cells that were mature PLP-positive oligodendrocytes versus immature Nkx2.2-positive OLPs (Fig. 7d,e ). XAV939 treatment did not affect the inflammatory cell or astrocyte infiltration into lesions (Fig. 7f) , nor early OLP recruitment or proliferation in the lesion (Fig. 7h,i) . Such precocious OLP differentiation in XAV939-treated lesions was associated with significantly thicker (P < 0.0001) myelin sheaths (smaller g ratios) than in controls at 10 dpl, when myelin sheath formation is on-going (Fig. 7j) . Myelin thickness in XAV939-treated remyelinated lesions was similar to controls when lesions in both groups were fully remyelinated at 28 dpl (Supplementary Fig. 12) . These findings indicate that XAV939 treatment substantially accelerates the processes of OLP differentiation and compact myelin formation in vivo. 
DISCUSSION
Despite advances in neonatal intensive care in developed countries, newborn brain injuries such as HIE in full-term infants and PVL in very premature infants remain leading causes of cerebral palsy and cognitive disability. Indeed, the incidence of these conditions is rising (http://www.cdc.gov/ncbddd/dd/cp3.htm#common/), owing to the increasing survival of extremely low birth-weight premature infants born at gestational ages <28 weeks. Although WMI and demyelination is primary in multiple sclerosis, it is also an important component of HIE and PVL. Progression in multiple sclerosis lesions to a stage of chronic demyelination is thought to reflect both autoimmune-mediated damage to oligodendrocytes and inefficient repair. In both multiple sclerosis 5, 6 and PVL 8, 9 , there is evidence for 'stalled' oligodendrocyte precursors that fail to engage in remyelination.
The presence of AXIN2-and Nkd1-positive OLPs in neonatal HIE and PVL as well as multiple sclerosis, suggests a generalized Wnt pathway activation response in white matter to diverse types (toxic, autoimmune and hypoxic) of injury. However, further work is needed to confirm this proposal in other human neuropathological conditions (for example, spinal cord injury). Because Axin2 expression serves as both a readout of the Wnt pathway and a feedback inhibitor, the presence of Axin2-positive OLPs likely indicates cells attempting to myelinate axons. Our results indicate that Axin2 is a potent regulator of the timing of remyelination, an important determinant of effective repair and functional recovery in human multiple sclerosis and animal models 27 . Several lines of evidence indicate that the Wnt pathway acts cell autonomously in OLPs. First, we previously activated β-catenin in OLPs in vivo and observed delayed differentiation 10 . Second, dispersed cultures of Axin2 −/− OLP showed delayed differentiation. Third, wild-type OLP cultures treated with XAV939 showed accelerated differentiation (Supplementary Fig. 13) .
It is unclear whether the effect of dysregulated Wnt signaling is sufficient to account for stalled OLP maturation or, as is more likely, that Wnt signals are amongst several factors that may be involved. The abnormal environment of a demyelinated axon tract, containing inflammatory cells, myelin debris 28 and other factors 1 0 1 6 VOLUME 14 | NUMBER 8 | AUGUST 2011 nature neurOSCIenCe a r t I C l e S (for example, Lingo-1 (ref. 29) , Notch 30 signaling), appear to also inhibit remyelination. Delayed remyelination kinetics might lead to chronic demyelination 23 , in keeping with recent studies showing that oligodendrocytes initiate new myelin segments only during a temporally restricted developmental window 31 .
Despite probably complex roles of multiple factors in remyelination, treatment with XAV939 alone was sufficient to stabilize Axin proteins and promote markedly accelerated oligodendrocyte differentiation after demyelinating injury. Our results from Axin2 −/− mice indicate that XAV939 acts specifically through its effects on Axin2, and our in vitro findings suggest that this acts to inhibit the canonical Wnt pathway through β-catenin phosphorylation/degradation. XAV939 was non-toxic to OLPs at early stages of recruitment and proliferation and acted to accelerate differentiation and formation of compact myelin. These findings indicate that Wnt pathway activity is dispensable for myelin regeneration.
Our therapeutic approach employed targeted injection of XAV939 into spinal cord lesions. Although this approach might seem to present technical challenges, we note that non-invasive imaging currently allows for precise neurosurgical placement of devices, neural progenitor cells and drugs directly into white matter tracts of the brain. In preliminary studies, we observed upregulation of Tcf4, Axin2, Nkd1 and Notum in the white matter of neonatal mice exposed to chronic hypoxia, and Axin2 −/− animals sustained permanent deficits in white matter after such injury (J.C.S., E.P.H., S.P.J.F. and D.H.R., unpublished observations). XAV939 treatment promoted robust myelination of axons after cerebellar cultures were exposed to hypoxia, highlighting the efficacy of XAV939 to act on OLPs from the brain to promote myelination after a developmental hypoxic insult. Further study of systemic XAV939 (and similar agents that stabilize Axin2) administration is needed to determine possible toxicity and efficacy in promoting remyelination in pre-clinical models of human neonatal hypoxic WMI and adult demyelinating diseases 32 .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/. Accession codes. Microarray data are available on the GEO website, GSE19403.
Note: Supplementary information is available on the Nature Neuroscience website.
